# Efficacy and Safety of Shexiang Baoxin Pill in Patients With Ischemia With Non-Obstructive Coronary Artery

Study · id `cardio:ct-nct04897126` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04897126](<https://clinicaltrials.gov/study/NCT04897126>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT04897126

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 240 participants.

## Technical summary

Registry record NCT04897126. Randomized; quadruple masking; primary purpose treatment. Start 2021-05-11 (actual); primary completion 2023-07-04 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 240 participants (enrolled count; ClinicalTrials.gov record NCT04897126, source copy `cardio:ctgov-nct04897126-2024-04-23`, retrieved 2026-11-18)
- Started: 2021-05-11 (actual) (ClinicalTrials.gov record NCT04897126, source copy `cardio:ctgov-nct04897126-2024-04-23`, retrieved 2026-11-18)
- Primary completion: 2023-07-04 (actual) (ClinicalTrials.gov record NCT04897126, source copy `cardio:ctgov-nct04897126-2024-04-23`, retrieved 2026-11-18)
- Completion: 2023-10-25 (actual) (ClinicalTrials.gov record NCT04897126, source copy `cardio:ctgov-nct04897126-2024-04-23`, retrieved 2026-11-18)
- Countries: China (ClinicalTrials.gov record NCT04897126, source copy `cardio:ctgov-nct04897126-2024-04-23`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04897126-2024-04-23`, retrieved 2026-11-18)

## The registry's words

- Brief title: Efficacy and Safety of Shexiang Baoxin Pill in Patients With Ischemia With Non-Obstructive Coronary Artery
- Acronym: LESS
- Condition: Ischemia With Non-Obstructive Coronary Artery
- Condition: Angina Pectoris
- Condition: Coronary Heart Disease
- Condition: X Syndrome, Angina
- Intervention (Radiation): Shexiang Baoxin pill（MUSKARDIA）
- Intervention (Radiation): Placebo
- Lead sponsor: Shanghai Hutchison Pharmaceuticals Limited
- Lead sponsor class: INDUSTRY
- Collaborator: Shanghai Changzheng Hospital
- Collaborator class: OTHER
- Collaborator: Second Affiliated Hospital of Bengbu Medical College
- Collaborator class: OTHER
- Collaborator: The Second Affiliated Hospital of Jiaxing University
- Collaborator class: OTHER
- Collaborator: Zibo Municipal Hospital
- Collaborator class: OTHER
- Collaborator: Affiliated Hospital of Liaoning University of Traditional Chinese Medicine
- Collaborator class: OTHER
- Collaborator: Shanxi Cardiovascular Hospital
- Collaborator class: OTHER
- Collaborator: The First Hospital of Hebei Medical University
- Collaborator class: OTHER
- Collaborator: Tangshan Central Hospital
- Collaborator class: OTHER
- Collaborator: Tie Fa Coal Group Ceneral Hospital of Liaoning Health Industry Group
- Collaborator class: UNKNOWN
- Collaborator: Ceneral Hospital Of Benxi Iron And Steel of Liaoning Health Industry Group
- Collaborator class: UNKNOWN
- Collaborator: General Hospital of Fuxin Mining Industry Group of Liaoning Health Industry Group
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Angina pectoris (`cardio:angina-pectoris`)
- Registry lists this organization as the lead sponsor: Shanghai Hutchison Pharmaceuticals Limited (`cardio:org-shanghai-hutchison-pharmaceuticals-limited`)
- Registry lists this organization as a collaborator: Shanghai Changzheng Hospital (`cardio:org-shanghai-changzheng-hospital`)
- Registry lists this organization as a collaborator: The Second Affiliated Hospital of Jiaxing University (`cardio:org-the-second-affiliated-hospital-of-jiaxing-university`)
- Registry lists this organization as a collaborator: Affiliated Hospital of Liaoning University of Traditional Chinese Medicine (`cardio:org-affiliated-hospital-of-liaoning-university-of-traditional-f9a547`)
- Registry lists this organization as a collaborator: Shanxi Cardiovascular Hospital (`cardio:org-shanxi-cardiovascular-hospital`)
- Registry lists this organization as a collaborator: The First Hospital of Hebei Medical University (`cardio:org-the-first-hospital-of-hebei-medical-university`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy and safety of Shexiang Baoxin Pill in patients with angina and non-obstructive coronary arteries: A multicenter, randomized, double-blind, placebo-controlled, phase Ⅳ clinical trial (`cardio:pubmed-40020628`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 048b9f59f575b892462744a3ea5c48df870ca041e3698b23a92db3962a46117b
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
